Nivolumab plus chemo and immune drug for unresectable liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 1/2 trial tests whether nivolumab combined with fluorouracil and interferon alpha can treat fibrolamellar liver cancer that cannot be safely removed with surgery. It aims to shrink or control the cancer and to see how safe the combination is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal guardian) can sign consent, and if under 18 you can assent too
- Your diagnosis is confirmed fibrolamellar hepatocellular carcinoma (FLHCC)
- Your cancer is not removable by surgery, but you may have disease outside the liver
- You have at least one measurable tumor area (meeting size cutoffs on CT/MRI or standard scans)
- Your blood counts and liver/kidney labs are within required limits, including good liver function (Child-Pugh A)
- You can safely take study treatment based on overall health and immune/autoimmune factors (no major uncontrolled conditions)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs, nivolumab and ipilimumab, as a first treatment for liver cancer that cannot be removed by surgery or has come back after local treatments.
This study tests a new way of giving immunotherapy drugs for advanced liver cancer that cannot be removed by surgery. The goal is to find the best dose for each patient, which may help control the cancer with fewer side effects.
This trial tests a vaccine targeting a specific fusion protein found in fibrolamellar carcinoma, combined with two immunotherapy drugs and a glutamine blocker. It is for patients whose cancer has gotten worse despite previous treatment.
This Phase 1 trial tests a personalized peptide vaccine (targeting the DNAJB1-PRKACA fusion) combined with immunotherapy drugs to treat fibrolamellar hepatocellular carcinoma (FLC) or other eligible non-FLC cancers with the same gene fusion. It aims to see whether this immune-based treatment can shrink tumors and improve outcomes safely.
This trial tests a combination of treatments for people with liver cancer that can be surgically removed. The goal is to see if the combination helps shrink tumors and improve outcomes before surgery.
This trial studies whether ABX196 combined with nivolumab can slow or treat advanced hepatocellular carcinoma (liver cancer) when it can’t be fully cured with surgery or local procedures. It’s early-phase, so the goal is to find the best way to treat and whether it shows signs of benefit.
Hear when a new Stage III Hepatocellular Carcinoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.